Showing results (51-60 of 70) with videos related to
Sort By:
Pageof 7
Oncotarget|January 16, 2016
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cellsIgor Vujic, Martina Sanlorenzo, Rosaura Esteve-Puig, et al.Leukemia Research|June 6, 2025
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)Brian A Jonas, Samantha C Fisch, Peter T Curtin, et al.American Journal of Hematology|July 13, 2017
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphomaThomas E Witzig, Pier Luigi Zinzani, Thomas M Habermann, et al.Oncotarget|October 4, 2014
Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapiesIgor Vujic, Christian Posch, Martina Sanlorenzo, et al.British Journal of Haematology|February 28, 2009
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphomaThomas M Habermann, Izidore S Lossos, Glen Justice, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2019
A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell LymphomaJoseph M Tuscano, Emanual Maverakis, Susan Groshen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphomaPeter H Wiernik, Izidore S Lossos, Joseph M Tuscano, et al.Clinical Lymphoma, Myeloma & Leukemia|January 22, 2021
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I TrialSwetha Kambhampati, Bita Fakhri, Weiyun Z Ai, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyCarol M Richman, Sally J Denardo, Robert T O'Donnell, et al.Leukemia Research|June 23, 2022
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer centerTamer Othman, Benjamin N Moskoff, Gwendolyn Ho, et al.Pageof 7